Evidence map›Paper›PMID 39154106›Full record

Trial reportArchives of dermatological research2024

Assessing the efficacy and quality of Life improvements of botulinum toxin type a with topical minoxidil versus topical minoxidil in male androgenetic alopecia: a randomized controlled trial.

Linli Yu, Sathishkumar Moorthy, Xutong Li, Lin Peng, Zikai Zhang, Liangliang Shen, Yu Han, Xin Huang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linli Yu *Department of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Sathishkumar Moorthy *Department of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Xutong LiDepartment of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Lin PengDepartment of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Zikai ZhangDepartment of Science, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Liangliang ShenDepartment of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Yu HanDepartment of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China.
Xin HuangDepartment of Dermatology, Tongji Hospital, School of Medicine, Hair Medical Center of Shanghai Tongji Hospital, Tongji University, Shanghai, 200065, China. alida_huang@163.com.

Funding

Clinical Research Plan of SHDC SHDC22022302National Natural Science Foundation of China 82073452Natural Foundation Project of Shanghai Science and Technology Commission 17ZR1426300Shanghai General Hospital Integrated Traditional Chinese and Western Medicine Special Project ZHYY-ZXYJHZX-202002Shanghai Tongji Hospital Clinical "Five New" Innovation R&D Project ITJ(ZD)2306Shanghai Tongji Hospital Clinical Research and Cultivation Key Project ITJ(ZD)1903
6 · The paper itself

Abstract

Androgenetic alopecia (AGA) is a common type of hair loss in men and efficacy and safety of current medical treatment remain limited. Therefore, the present study aimed to investigate the efficacy and safety of botulinum toxin type A (BTA) combined with Minoxidil in patients with AGA. 60 male patients were included in this study and control group received topical 5% Minoxidil and the treatment group received BTA combined with topical 5% Minoxidil. BTA injections (60-70 U) were administered at 30-35 scalp sites. Head photographs were taken at baseline, 2nd, 4th, and 6th months. Clinical descriptions recorded scalp conditions, and patient satisfaction along with Dermatology Life Quality Index scores were documented. The treatment group (TG) showed significant hair growth differences compared to the control group (CG) at the 4th month (P < 0.001) and 6th month (P = 0.0046) post-treatment. TG had improved Investigator Global Assessment (IGA) scores in the 4th month (P = 0.0001) and 6th month (P = 0.0259) compared to CG. Patient satisfaction in TG for hair growth and scalp improvement was higher than CG (all P < 0.05). TG exhibited substantial quality of life improvement at the 4-month (P = 0.0009) and 6-month (P = 0.0099). No adverse reactions were observed post-botulinum toxin injection. BTA combined with Minoxidil effectively promotes hair growth, enhances the quality of life, and alleviates scalp symptoms in male AGA patients at 4th and 6th months, with no adverse effects compared to Minoxidil alone.Trial registration number: Ethics Committee of Shanghai Tongji Hospital (ID: K-2018-026).

Indexed as

AlopeciaBotulinum Toxins, Type AMinoxidilPatient SatisfactionQuality of LifeAdministration, TopicalAdultDrug Therapy, CombinationHairHumansMaleMiddle AgedScalpTreatment OutcomeYoung AdultBotulinum Toxins, Type AMinoxidilAndrogenetic alopeciaBotulinum toxin type AMinoxidilQuality of life

Identifiers

PMID39154106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.